Solara’s Mangalore Site Clears US FDA Inspection with VAI Status
POWER & RENEWABLE ENERGY

Solara’s Mangalore Site Clears US FDA Inspection with VAI Status

Solara Active Pharma Sciences has announced the successful completion of the US Food and Drug Administration (US FDA) inspection at its multi-product Active Pharmaceutical Ingredient manufacturing facility in Mangalore, Karnataka. The inspection, conducted from 25 to 29 August 2025, concluded with the issuance of an Establishment Inspection Report (EIR) on 18 November 2025. The Agency classified the facility as “Voluntary Action Indicated” (VAI), confirming continued compliance with current Good Manufacturing Practices (cGMP) and formally closing the inspection.

According to the company, the US FDA issued two procedural Form 483 observations at the end of the inspection. Solara submitted a comprehensive response within the stipulated timeframe, following which the Agency acknowledged the adequacy of the corrective actions and closed the inspection. The company noted that the outcome reflects its commitment to regulatory excellence, robust quality systems and adherence to global compliance standards across all manufacturing sites.

The Mangalore facility is equipped with multiple independent production blocks and packaging units, enabling supply of a wide portfolio of APIs. It is also regularly inspected by leading global regulatory bodies, including EDQM, HPRA, TGA, WHO, PMDA and MFDS Korea. Solara stated that maintaining world-class quality and compliance remains central to its long-term growth strategy.

"Join industry leaders at RAHSTA Expo, India's premier platform for roads, highways and traffic infrastructure. Register now to explore innovations, network with experts and shape the future of mobility."

Solara Active Pharma Sciences has announced the successful completion of the US Food and Drug Administration (US FDA) inspection at its multi-product Active Pharmaceutical Ingredient manufacturing facility in Mangalore, Karnataka. The inspection, conducted from 25 to 29 August 2025, concluded with the issuance of an Establishment Inspection Report (EIR) on 18 November 2025. The Agency classified the facility as “Voluntary Action Indicated” (VAI), confirming continued compliance with current Good Manufacturing Practices (cGMP) and formally closing the inspection. According to the company, the US FDA issued two procedural Form 483 observations at the end of the inspection. Solara submitted a comprehensive response within the stipulated timeframe, following which the Agency acknowledged the adequacy of the corrective actions and closed the inspection. The company noted that the outcome reflects its commitment to regulatory excellence, robust quality systems and adherence to global compliance standards across all manufacturing sites. The Mangalore facility is equipped with multiple independent production blocks and packaging units, enabling supply of a wide portfolio of APIs. It is also regularly inspected by leading global regulatory bodies, including EDQM, HPRA, TGA, WHO, PMDA and MFDS Korea. Solara stated that maintaining world-class quality and compliance remains central to its long-term growth strategy.

Next Story
Real Estate

Pecan Realty Completes Rs 1.5 Billion Transactions

Pecan Realty has recently completed four institutional transactions worth over Rs 1.5 billion over the past two years, strengthening its position as an execution-led real estate platform. The deals include resolution-led acquisitions, structured finance transactions and capital partnerships across its development portfolio.The transactions covered acquisitions through the National Company Law Tribunal process and helped provide repayment or exits to both private and public sector lenders. The company said the deals demonstrate its ability to resolve complex project situations, work with instit..

Next Story
Real Estate

SNN Estates Expands North Bengaluru Housing Project

SNN Estates has announced an expansion of its SNN Estates Felicity residential project in North Bengaluru following strong buyer demand, with 75 per cent of the first-phase inventory sold within three days of launch.The developer will add 76 apartments in the new phase, taking the project's estimated revenue potential to around Rs 1,000 crore upon completion of Phase 2.Spread across 6.5 acres in Rachenahalli, near Manyata Tech Park, the project comprises 604 apartments in 1.5, 2, 2.5, 3 and 4 BHK configurations. The development includes a 50,000-sq-ft clubhouse with amenities such as sports co..

Next Story
Infrastructure Urban

SCG Drives ASEAN Industrial Transformation Strategy

SCG is strengthening its focus on ASEAN as a key growth region by advancing industrial transformation, enhancing competitiveness and building resilient regional value chains. Thammasak Sethaudom, President and Chief Executive Officer, SCG, highlighted the need for industries to continuously develop capabilities, strengthen resilience and deepen regional cooperation to achieve sustainable long-term growth.SCG views ASEAN as an important growth engine alongside China, supported by favourable demographics, trade connectivity and investment flows. With ASEAN’s GDP projected to grow by around 4.7..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement